Last reviewed · How we verify

NCT06090825

Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

Status unknown Last updated 19 October 2023
What this trial tests

trial testing Observational study in Pancreatic Cancer in 450 participants. Status unknown.

Timeline
1 September 2023
Primary endpoint
1 September 2024
1 September 2025

Quick facts

Lead sponsorPeking Union Medical College Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment450
Start date1 September 2023
Primary completion1 September 2024
Estimated completion1 September 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

Eligibility, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observational study

Trials testing the same drug.

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06090825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing